DNA-Probe Rapidly Screens for MRSA

An accurate, easy-to-use DNA-probe screening test for methicillin resistant Staphylococcus aureus (MRSA) provides sample-to-answer results in less than three hours.

The Detect-Ready MRSA kit is a qualitative real time- polymerase chain reaction (RT-PCR) in vitro diagnostic (IVD) test for the direct detection of MRSA nasal colonization. It will aid in the prevention and control of MRSA infections in hospitals and other healthcare settings.

The technology in the Detect-Ready kits provides a unique differential diagnosis engine that produces highly accurate results, minimizing false positives and false negatives. Samples for testing are simple to obtain using nasal swabs and the assay's ready-to-use premixed reagents require only the addition of patient sample to run the test.

Off-the-shelf room temperature-stabilized and requiring no refrigeration, Detect-Ready kits are compatible with multiple RT-PCR platforms found in clinical laboratories. This flexibility to leverage existing infrastructure and equipment to run Detect-Ready assays eliminates the need for additional hospital capital investment.

Molecular Detection Inc. (MDI; Wayne, PA, USA; and Jerusalem, Israel) and Inverness Medical Deutschland GmbH (Cologne, Germany) have entered into an exclusive distribution agreement for MDI's Detect-Ready MRSA assay in Germany, Austria, and Switzerland.

MDI is a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis.

Inverness Medical Deutschland, a leading distributor of medical diagnostic products in European markets, is a subsidiary of Inverness Medical Innovations, Inc. a global market leader in point-of-care diagnostics.

Related Links:
Molecular Detection Inc.
Inverness Medical Deutschland GmbH
Inverness Medical Innovations, Inc.